📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-10 18:46
666 analysed today
666
Today
133,555
All-time analysed
40,122
Positive
6,284
Negative
79,331
Neutral
7,750
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
19 announcements match the current filters (relevance ≥ 5).
ION Exchange Restructures Segments; Plans 2X Resin Capacity Expansion at Roha
ION Exchange has restructured its reporting into five granular segments to improve transparency, revealing that Specialty Chemicals is the primary profit driver with Rs 177 Cr EBIT in FY26. The company is executing a 2X capacity expansion in Industrial Resins at Roha, featuring India's first non-solvent resin facility. While Treatment Solutions revenue grew at a 23% CAGR to Rs 1,122 Cr, its EBIT has declined significantly from Rs 60 Cr in FY22 to Rs 27 Cr in FY26. International operations now contribute 30% of total revenue, supported by 14 global manufacturing and assembly centers.
Confidence: HIGH
What changedThe company has transitioned from three broad reporting segments to five specialized segments and provided a roadmap for doubling its resin manufacturing capacity.
Why it mattersThe new segmentation highlights that the company's profitability is heavily reliant on Specialty Chemicals and Services, while the core Engineering (Treatment) business is facing margin headwinds despite revenue growth.
FY26 Total Revenue: Rs 2915 CrSpecialty Chemicals EBIT: Rs 177 CrTreatment Solutions EBIT: Rs 27 CrInternational Revenue Share: 30%Resin Capacity Expansion: 2X
📅 Short termThe market may focus on the declining EBIT in the Treatment Solutions and Consumer segments despite healthy top-line growth.
📈 Long termThe 2X resin expansion and focus on high-margin Lifecycle Services (21% EBIT CAGR) could structurally improve the company's ROE if the engineering margins stabilize.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Significant EBIT contraction in Treatment Solutions (from Rs 60 Cr to Rs 27 Cr in 4 years)
- Suez Canal route constraints impacting European delivery timelines
- Continued losses in the Consumer Products segment (-Rs 10 Cr EBIT in FY26)
Key Highlights
Restructured reporting into 5 segments: Treatment Solutions, Industrial Products, Lifecycle Services, Specialty Chemicals, and Consumer Products.
Specialty Chemicals segment generated Rs 177 Cr EBIT on Rs 868 Cr revenue in FY26, maintaining a 10% EBIT CAGR.
Treatment Solutions segment revenue reached Rs 1,122 Cr in FY26, but EBIT margins have compressed to a -18% CAGR over four years.
Doubling (2X) capacity for Industrial Resins at Roha to target a global market share increase from 2% to 5%.
Lifecycle Services segment showed strong growth with a 21% EBIT CAGR, reaching Rs 38 Cr in FY26.
👀 What to Watch
Monitor the margin recovery in the Treatment Solutions segment and the execution timeline of the Roha resin plant expansion, which is critical for global market share gains.
ION Exchange Q1 FY27: Revenue up 20% to ₹700 Cr, but PAT drops 93% on margin pressure
ION Exchange reported a 20.1% YoY increase in consolidated revenue to ₹700.5 Cr for Q1 FY27. However, profitability was severely impacted, with consolidated PAT dropping 93.6% to ₹3.1 Cr compared to ₹48.4 Cr in the same quarter last year. The decline was driven by a 622 bps contraction in EBITDA margins to 4.54%, primarily due to legacy project costs in the Treatment Solutions segment and higher depreciation from the Roha facility. Despite the earnings miss, the company maintains a healthy order book of ₹2,473 Cr and a massive bid pipeline of ₹9,777 Cr.
Confidence: HIGH
What changedThe company reported a significant divergence between revenue growth and profitability, alongside a transition to a new reporting segment structure (Institutional, Engineering, Chemicals, Consumer).
Why it mattersThe sharp drop in PAT despite revenue growth indicates execution challenges and cost pressures in the engineering segment, which could delay the benefits of recent capacity expansions.
Q1 Consolidated Revenue: ₹700.5 CrQ1 Consolidated PAT: ₹3.1 CrEBITDA Margin: 4.54%Order Book: ₹2,473 CrBid Pipeline: ₹9,777 CrHyundai Order Value: $52.83 Mn
📅 Short termThe stock is likely to face negative sentiment in the short term due to the substantial earnings miss and severe margin contraction.
📈 Long termStructural growth remains supported by a large bid pipeline and capacity expansions in membranes and resins, but long-term value depends on returning to double-digit EBITDA margins.
⚠ Risk flags
- Margin pressure from legacy engineering projects
- Geopolitical impacts on specialty chemical exports
- Increased depreciation and finance costs from new facilities
Key Highlights
Consolidated revenue grew 20.1% YoY to ₹700.5 Cr, though it declined 18.9% sequentially.
Consolidated PAT fell sharply to ₹3.1 Cr from ₹48.4 Cr YoY, a 93.6% decline.
Operating EBITDA margins contracted significantly to 4.54% from 10.75% in Q1 FY26.
Total outstanding order book stands at ₹2,473 Cr, excluding a recent $52.83 Mn (approx. ₹440 Cr) Hyundai order.
Bid pipeline remains robust at ₹9,777 Cr, providing visibility for future order inflows.
👀 What to Watch
Investors should monitor the timeline for liquidating low-margin 'legacy projects' in the Treatment Solutions segment, which is currently dragging down overall profitability. The ramp-up of the Roha resin plant and the execution of the new $52.83 Mn Hyundai order are key triggers to watch for margin recovery.
ION Exchange Targets 10% Global Resin Market Share; Plans 5X Capacity Expansion at Roha
ION Exchange is aggressively scaling its resin business, targeting a global market share increase from 2.5% to 10% through a 5X capacity expansion at its Roha facility. Despite TTM revenue growth to Rs 2,915 Cr, FY26 EBIT margins faced pressure, with the Specialty Chemicals segment EBIT dropping from Rs 207 Cr to Rs 177 Cr year-on-year. The company is reorganizing into five new reporting segments to improve operational focus. International operations remain a key pillar, contributing 30% of total revenue across 50+ countries.
Confidence: HIGH
What changedThe company has formalized a 10% global market share target for resins and is transitioning to a new five-segment financial reporting structure.
Why it mattersThe 5X and 4X capacity expansions represent a significant scale-up of the company's high-margin resin business, intended to offset recent margin compression in the engineering and chemical segments.
Global Resin Market Share Target: 10%Industrial Resin Capacity Expansion: 5XInternational Revenue Share: 30%FY26 Consolidated Revenue: Rs 2914.57 CrTTM OPM: 7.2%
📅 Short termThe stock may see neutral to cautious sentiment as the presentation highlights EBIT declines in major segments (Chemicals and Engineering) for FY26 despite higher revenues.
📈 Long termStructural growth depends on the successful execution of the 5X resin capacity expansion and the ability to leverage the Mapril acquisition for European market penetration.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Margin compression in core engineering and chemical segments
- Supply chain risks due to Suez Canal constraints impacting European exports
- Continued EBIT losses in the Consumer Products segment
Key Highlights
Targeting a 4x increase in global resin market share from current 2.5% to 10%
Executing a 5X capacity expansion for Industrial Resins at the Roha facility
Executing a 4X capacity expansion for Pharma Resins at the Ankleshwar facility
Consumer Products segment revenue grew 31% to Rs 343 Cr in FY26, though it remains EBIT negative at -Rs 10 Cr
Specialty Chemicals segment revenue reached Rs 868 Cr in FY26, contributing ~30% of total revenue
👀 What to Watch
Monitor the commissioning and ramp-up timeline of the Roha greenfield resin plant, as this is the primary driver for the 10% global market share target. Investors should also watch for margin recovery in the Treatment Solutions segment, where EBIT fell from Rs 30 Cr to Rs 27 Cr despite revenue growth.
ION Exchange Q1 PAT Drops 75% YoY to ₹11.4 Cr Despite 23% Revenue Growth
ION Exchange reported a 22.7% YoY increase in standalone revenue to ₹635.56 Cr for Q1 FY27, but standalone net profit plummeted 75.7% to ₹11.40 Cr. The profitability decline was driven by a 41.2% surge in 'Other Expenses' and a nearly 5x spike in finance costs to ₹8.21 Cr. Consolidated profit before tax saw an even sharper decline of 89% YoY to ₹6.99 Cr. Strategically, the company has reorganized its Engineering segment into three new units—Treatment Solutions, Industrial Products, and Lifecycle Services—to pivot toward technology-led solutions.
Confidence: HIGH
What changedThe company has realigned its reporting structure, splitting the Engineering segment into three specialized units, while experiencing significant margin compression due to higher input and finance costs.
Why it mattersThe sharp drop in profitability despite revenue growth suggests operational inefficiencies or high upfront costs for its strategic pivot; the 5x jump in finance costs indicates increased debt servicing or working capital needs.
Standalone Revenue (Q1 FY27): ₹635.56 CrStandalone PAT (Q1 FY27): ₹11.40 CrYoY Revenue Growth: 22.7%YoY PAT Growth: -75.7%Finance Cost Increase: 394.6%Q1 Revenue vs TTM Revenue: 21.8%
📅 Short termThe stock is likely to face downward pressure in the short term due to the significant earnings miss and severe margin contraction.
📈 Long termThe transition to a technology-led solutions provider and expansion in Specialty Chemicals (assets up 30% YoY) could improve structural margins, but execution remains a key risk.
⚠ Risk flags
- Severe margin contraction
- Sharp increase in finance costs
- High growth in other operating expenses
- Consolidated performance significantly weaker than standalone
Key Highlights
Standalone Revenue grew 22.7% YoY to ₹635.56 Cr from ₹517.83 Cr
Standalone Net Profit fell 75.7% YoY to ₹11.40 Cr from ₹46.88 Cr
Finance costs increased by 394.6% YoY to ₹8.21 Cr from ₹1.66 Cr
Other Expenses rose 41.2% YoY to ₹103.58 Cr
Consolidated Profit Before Tax fell 89.3% YoY to ₹6.99 Cr from ₹65.46 Cr
👀 What to Watch
Investors should monitor the margin recovery in the newly formed 'Lifecycle Services' and 'Specialty Chemicals' segments and watch for the commissioning timeline of the Roha resin plant to offset current cost pressures.
Rs 503 Cr International Order Win from Hyundai Engineering for Middle East Project
ION Exchange (India) Limited has secured a significant international contract worth approximately Rs 503 crore (USD 52.83 million) from Hyundai Engineering & Construction Co. Ltd. The contract involves the supply of filtration units for a project in the Middle East, with an execution timeline of 18 months. This order represents approximately 17.3% of the company's TTM revenue of Rs 2,915 crore, providing strong revenue visibility for the next six quarters. The win aligns with the company's strategy to consolidate its market position in the Gulf region.
Confidence: HIGH
What changedION Exchange has transitioned from domestic-heavy bidding to securing a large-scale international supply contract with a global major like Hyundai Engineering.
Why it mattersThis contract provides substantial revenue visibility and validates the company's technical capability in the filtration segment on an international stage, supporting its 12-15% growth target.
Order Value: Rs 503 crOrder vs TTM Revenue: 17.3%Execution Timeline: 18 monthsTTM Revenue: Rs 2915 cr
📅 Short termThe announcement is likely to be viewed positively by the market in the coming days as it strengthens the order book significantly.
📈 Long termSuccessful execution could lead to more high-value international contracts and help the company achieve its goal of expanding its footprint in the Gulf and North Africa.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Suez Canal route constraints impacting delivery timelines
- Currency fluctuation risks associated with USD-denominated contracts
- Execution risks in international geographies
Key Highlights
Awarded an international contract worth USD 52.83 million (approx. INR 503 crore) by Hyundai Engineering & Construction Co. Ltd.
The project involves the supply of filtration units specifically for the Middle East market.
Execution is scheduled over a period of 18 months, providing steady revenue flow through late 2027.
The order value constitutes approximately 17.3% of the company's total TTM revenue of Rs 2,915 crore.
👀 What to Watch
Investors should monitor the company's quarterly execution progress and operating margins, as engineering segment EBIT margins have recently faced pressure at 4.8%.
Ion Exchange Q4 FY26: Revenue Up 3% to ₹863 Cr; FY26 EBITDA Drops 29% on Margin Pressure
Ion Exchange (India) Limited reported a consolidated revenue of INR 8,633 million for Q4 FY26, a 3% YoY increase, though full-year EBITDA fell 29% to INR 2,102 million due to rising input costs and geopolitical disruptions. The engineering order book remains strong at INR 26,433 million, bolstered by a major OMR 73.46 million contract in Oman and a USD 18.1 million project in Malawi. Management is focusing on high-tech membrane segments through a new partnership with MANN+HUMMEL and expects the newly commissioned Roha facility to reach 25% utilization in the coming year.
Key Highlights
FY26 consolidated revenue reached INR 29,148 million (+7% YoY), but EBITDA margins contracted to 7.21% from the previous year.
Engineering order book stands at a healthy INR 26,433 million as of March 31, 2026, providing strong revenue visibility.
The company entered a strategic technology transfer and manufacturing collaboration with MANN+HUMMEL for ultra-filtration membranes.
West Asia crisis impacted Q4 margins due to deferred export shipments worth approximately INR 600 million and higher raw material costs.
Consumer Product Division showed strong growth with revenue increasing 34% YoY to INR 1,047 million in Q4.
👀 What to Watch
Investors should focus on the company's ability to pass on increased input costs and the ramp-up of the Roha facility to improve margins. While the order book is robust, short-term profitability remains sensitive to geopolitical stability in West Asia and logistics costs.
Ion Exchange Recommends Rs 1.25 Dividend; Appoints New Cost Auditors for FY27
Ion Exchange (India) Limited has reported its audited financial results for the year ended March 31, 2026, receiving an unmodified opinion from statutory auditors Deloitte Haskins & Sells LLP. The Board has recommended a dividend of Rs. 1.25 per share (125% of face value) for the fiscal year. Additionally, the company has appointed M/s. R. Nanabhoy & Co. as the new Cost Auditors for the 2026-27 financial year. The record date for the dividend payout has been set for August 31, 2026.
Key Highlights
Recommended a dividend of Rs. 1.25 per equity share (125%) for the financial year ended March 31, 2026.
Fixed August 31, 2026, as the record date for determining shareholder eligibility for the dividend.
Appointed M/s. R. Nanabhoy & Co. as Cost Auditors for the financial year 2026-27.
Statutory Auditors, Deloitte Haskins & Sells LLP, issued an unmodified opinion on standalone and consolidated FY26 results.
Financial results for the quarter and year ended March 31, 2026, were approved during a 9-hour board meeting.
👀 What to Watch
Investors should monitor the stock for the upcoming dividend payout and ensure holdings are in place before the August 31, 2026 record date. The clean audit report from a Big 4 firm (Deloitte) reinforces confidence in the company's financial reporting.
Ion Exchange Recommends Rs 1.25 Dividend; Sets August 31, 2026, as Record Date
Ion Exchange (India) Limited has recommended a final dividend of Rs 1.25 per equity share (125%) for the financial year ended March 31, 2026. The company has fixed August 31, 2026, as the record date to determine shareholder eligibility for this payout. The dividend is subject to shareholder approval at the upcoming Annual General Meeting and will be paid within 30 days of the meeting. Additionally, the board approved the audited financial results for FY26 and appointed new cost auditors.
Key Highlights
Recommended a dividend of Rs 1.25 per equity share of face value Re 1 (125% payout)
Fixed August 31, 2026, as the Record Date for dividend eligibility
Approved audited standalone and consolidated financial results for the year ended March 31, 2026
Appointed M/s. R. Nanabhoy & Co. as Cost Auditors for the financial year 2026-27
👀 What to Watch
Investors seeking dividend income should ensure they hold shares before the ex-dividend date preceding August 31, 2026. Monitor the full annual report for deeper insights into the company's growth trajectory.
ION Exchange Recommends Rs 1.25 Dividend and Approves FY26 Audited Financial Results
ION Exchange (India) Limited has approved its audited standalone and consolidated financial results for the fiscal year ended March 31, 2026. The Board recommended a dividend of Rs. 1.25 per equity share (125% of face value), with a record date set for August 31, 2026. The statutory auditors, Deloitte Haskins & Sells LLP, issued an unmodified opinion on the financial statements, indicating no major accounting discrepancies. Additionally, the company appointed M/s. R. Nanabhoy & Co. as Cost Auditors for the 2026-27 financial year.
Key Highlights
Recommended a dividend of Rs. 1.25 per equity share (125%) for the financial year ended March 31, 2026.
Fixed August 31, 2026, as the Record Date for determining dividend eligibility.
Statutory auditors issued an unmodified opinion on both standalone and consolidated financial results.
Appointed M/s. R. Nanabhoy & Co. as Cost Auditors for the financial year 2026-27.
The Board meeting concluded after a 9-hour session, indicating thorough review of financial performance.
👀 What to Watch
Investors should review the detailed profit and loss statements for margin trends and order book growth; the 125% dividend recommendation reflects a stable payout policy.
Ion Exchange Partners with MANN + HUMMEL for Advanced Membrane Technology Transfer
Ion Exchange (India) Limited has entered into a strategic Technology Transfer Agreement with MANN + HUMMEL to manufacture PVDF Ultrafiltration (UF) membranes and Membrane Bioreactor (MBR) systems. The production will be localized at Ion Exchange's expanded HYDRAMEM facility in Goa, aimed at reducing import dependence and improving supply reliability. As part of the agreement, the company will pay a technology transfer fee of 7.5% on the revenue generated from these specific manufactured products. This collaboration significantly strengthens the company's water treatment portfolio by integrating advanced UF, RO, and MBR technologies.
Key Highlights
Strategic tie-up with MANN + HUMMEL for technical know-how of PVDF Ultrafiltration and MBR systems
Manufacturing to be conducted at the expanded HYDRAMEM facility in Goa for domestic and international markets
Technology transfer fee fixed at 7.5% of revenue generated from the new product lines
Aims to offer globally benchmarked membrane technology locally, reducing reliance on imports
Strengthens the company's position in the high-growth water and wastewater treatment sector
👀 What to Watch
Investors should view this as a significant long-term growth driver that enhances the company's technical moat and margin potential through localization. Monitor the revenue contribution from the Goa facility's new product lines in upcoming quarters.
ION Exchange to Launch ESOP 2026 Scheme for 17 Lakh Shares via Secondary Acquisition
ION Exchange (India) Limited has issued a postal ballot notice to seek shareholder approval for its 'Employee Stock Option Scheme 2026'. The scheme proposes to grant up to 17,00,000 options, exercisable into an equal number of equity shares with a face value of Re. 1 each. Crucially, the scheme will be implemented through a Trust route involving secondary acquisition of shares, which prevents the dilution of existing equity. The options are intended for eligible employees of both the company and its subsidiaries to align their interests with long-term value creation.
Key Highlights
Proposed grant of up to 17,00,000 employee stock options under the new ESOP 2026 scheme.
Implementation via 'Ion Exchange ESOP Trust' using secondary market acquisition of shares to avoid equity dilution.
The scheme extends eligibility to employees of both the parent company and its various subsidiaries.
Remote e-voting for the special resolutions is scheduled from April 25, 2026, to May 24, 2026.
Results of the postal ballot will be declared on or before May 26, 2026.
👀 What to Watch
Investors should view this as a positive development for talent retention that avoids share dilution. No immediate action is required, but shareholders may monitor the voting results on May 26, 2026.
CRISIL Reaffirms ION Exchange Ratings; Bank Facilities Enhanced to Rs. 2099.74 Crore
CRISIL Ratings has reaffirmed the credit ratings for ION Exchange (India) Limited's bank facilities, signaling financial stability. The Long-Term rating is maintained at 'CRISIL A+/Stable' and the Short-Term rating at 'CRISIL A1'. Significantly, the total rated bank loan facilities have been increased from Rs. 1849.41 Crore to Rs. 2099.74 Crore. This reaffirmation suggests that the company's credit profile remains robust despite the expansion of its borrowing limits.
Key Highlights
Long-Term rating reaffirmed at 'CRISIL A+/Stable'
Short-Term rating reaffirmed at 'CRISIL A1'
Total bank loan facilities enhanced from Rs. 1849.41 Crore to Rs. 2099.74 Crore
The rating action covers an additional Rs. 250.33 Crore in bank facilities
👀 What to Watch
Investors should take comfort in the reaffirmed ratings which indicate stable creditworthiness. No immediate action is required as the credit profile remains unchanged.
ION Exchange Approves ESOP 2026 Scheme for 17 Lakh Shares via Secondary Acquisition
The Board of ION Exchange (India) Limited has approved the 'Employee Stock Option Scheme 2026' (ESOP 2026), involving 17,00,000 options. Each option is exercisable into one equity share of face value ₹1. Notably, the scheme will be implemented through an irrevocable employee welfare trust via secondary market acquisitions, ensuring no fresh equity dilution for existing shareholders. The exercise price will be determined by the committee with a maximum discount of 15% on the market price.
Key Highlights
Grant of 17,00,000 stock options to eligible employees under the new ESOP 2026 scheme.
Scheme to be implemented via secondary acquisition of shares through an Employee Welfare Trust.
Exercise price allows for a maximum discount of up to 15% on the market price at the time of grant.
Vesting period is set between a minimum of 1 year and a maximum of 4 years from the grant date.
The exercise period is capped at 4 years from the date of each vesting.
👀 What to Watch
Investors should view this as a positive move for talent retention without the risk of equity dilution. Monitor the company's financial statements for the impact of employee compensation expenses related to the trust's share purchases.
Ion Exchange Subsidiary Bags INR 1,730 Crore Order from Petroleum Development Oman
Ion Exchange (India) Limited's Oman-based subsidiary has secured a significant long-term contract from Petroleum Development Oman (PDO). The agreement covers the Design, Build, Own, Operation, and Maintenance (DBOOM) of potable water and sewage treatment facilities in the South PDO Concession Area. Valued at approximately INR 1,730 crores (OMR 73.46 million), the contract spans a 20-year period. This win significantly enhances the company's international order book and provides long-term revenue visibility.
Key Highlights
Total contract value of approximately INR 1,730 crores (OMR 73.46 million)
Long-term contract duration of 20 years providing steady revenue streams
Scope includes Design, Build, Own, Operation, and Maintenance (DBOOM) of water facilities
Awarded by Petroleum Development Oman to the company's Oman-based subsidiary
Strengthens the company's footprint in the Middle East water treatment market
👀 What to Watch
Investors should view this as a major positive development that secures long-term cash flows and validates the company's expertise in large-scale international projects. The stock may see positive momentum given the substantial order size relative to the company's annual turnover.
ION Exchange Q3 FY26: Revenue Up 6% to ₹7,344M, EBITDA Drops 21% on Roha Costs and Adverse Mix
ION Exchange reported a consolidated revenue of INR 7,344 million for Q3 FY26, a 6% YoY increase, but EBITDA fell 21% to INR 593 million. Profitability was significantly impacted by an exceptional item of INR 169 million for labor code provisions and higher depreciation/interest from the newly commissioned Roha facility. Despite margin pressure, the company maintains a strong order book of INR 28,330 million, with new solar sector wins totaling INR 2,050 million. Management expects a recovery in Q4 as deferred international engineering contracts are executed.
Key Highlights
Consolidated EBITDA margin contracted to 8.07% from 10.8% YoY due to Roha facility costs and rupee depreciation.
Engineering segment EBIT declined 28% YoY to INR 186 million, hampered by muted execution of UP Jal Nigam orders.
Chemical division revenue grew 16% YoY to INR 2,307 million, though EBIT fell 18% due to product mix and facility ramp-up.
Total order book stands at INR 28,330 million with a quarterly order inflow of INR 5,160 million.
Exceptional charge of INR 169 million recognized for employee benefits following the notification of new Labour Codes.
👀 What to Watch
Investors should monitor the utilization levels of the Roha facility and the execution pace of the high-margin international order book in Q4. While short-term margins are under pressure, the robust order book and alignment with government infrastructure spending provide a positive long-term outlook.
ION Exchange Q3 FY26: Net Profit Drops 58.5% YoY to ₹20.6 Cr Despite 6.4% Revenue Growth
ION Exchange reported a weak Q3 FY26 with consolidated revenue growing 6.4% YoY to ₹734.4 crore, but PAT plummeted 58.5% to ₹20.6 crore. Profitability was severely impacted by a sharp contraction in EBITDA margins, which fell to 8.07% from 10.92% YoY, and a ₹16.9 crore exceptional item. The engineering segment faced headwinds from deferred international dispatches and muted execution of the UP Jal Nigam order, although the bid pipeline remains strong at ₹9,556 crore. The chemicals segment saw revenue growth but margins were pressured by startup costs at the new Roha facility.
Key Highlights
Consolidated Operating Income rose 6.4% YoY to ₹7,344 Mn, while Operating EBITDA fell 21.4% to ₹593 Mn.
Net Profit (PAT) declined 58.5% YoY to ₹206 Mn, with PAT margins shrinking from 7.18% to 2.81%.
Engineering order book stands at ₹2,833 Cr with a massive bid pipeline of ₹9,556 Cr.
Chemicals segment revenue grew to ₹2,307 Mn, but EBIT was impacted by Roha facility costs and product mix.
Deferred international engineering contracts and slow UP Jal Nigam execution significantly hampered quarterly performance.
👀 What to Watch
Investors should exercise caution as the company faces significant margin pressure and execution delays in its engineering segment. While the bid pipeline is robust, the immediate focus should be on the stabilization of the Roha facility and the recovery of deferred international orders in Q4.
ION Exchange Q3 Standalone PAT Drops 55% YoY to ₹24.06 Cr; Impacted by Exceptional Item
ION Exchange reported a standalone revenue of ₹668.93 crore for Q3 FY26, representing a modest 3% growth compared to ₹649.93 crore in the same quarter last year. However, Profit After Tax (PAT) declined sharply by 55% YoY to ₹24.06 crore, down from ₹53.33 crore in Q3 FY25. This decline was significantly impacted by a one-time exceptional charge of ₹14.54 crore related to the implementation of new Labour Codes. Operating margins were also pressured by a 23% YoY increase in employee benefit expenses and higher finance costs.
Key Highlights
Standalone Revenue from operations grew 3% YoY to ₹668.93 crore but declined slightly on a QoQ basis.
Standalone PAT fell 55% YoY to ₹24.06 crore, with Basic EPS dropping from ₹4.34 to ₹1.96.
Recognized a one-time exceptional item of ₹14.54 crore due to increased gratuity and leave liabilities from new Labour Codes.
Total expenses rose to ₹636.51 crore from ₹587.76 crore in the previous year's quarter, driven by higher employee costs and depreciation.
Profit before tax (excluding exceptional items) stood at ₹46.67 crore, still significantly lower than the ₹72.93 crore reported in Q3 FY25.
👀 What to Watch
Investors should exercise caution as the sharp drop in profitability and rising operating expenses suggest margin pressure. It is important to monitor if the company can pass on these increased costs to customers in future quarters.
ION Exchange Wins Arbitration; ₹17.48 Crore Claim Dismissed
ION Exchange (India) Limited has received a favorable arbitral award regarding a long-standing dispute with Angeripalayam Common Effluent Treatment Plant Limited (ACETP). The claimant had sought ₹17.48 crores plus interest for alleged non-performance and consequential damages. The Sole Arbitrator dismissed the claim, along with the company's counter-claim, citing they were barred by the law of limitation. This outcome removes a significant contingent liability from the company's books, improving the risk profile of the balance sheet.
Key Highlights
Arbitral award dismissed a ₹17.48 crore claim against the company plus interest.
The dispute involved alleged non-performance of an Effluent Treatment Plant for ACETP.
Both the claim and the company's counter-claim were ruled as barred by the law of limitation.
The litigation was previously disclosed as a contingent liability in the company's financial accounts.
👀 What to Watch
This is a positive development as it eliminates a potential financial drain and legal uncertainty. Investors should view this as a reduction in risk for the company's balance sheet and a resolution of a legacy legal matter.
IONEXCHANG bags ₹205 Cr orders for water treatment projects
ION Exchange (India) Limited has secured contracts worth approximately ₹205 crores from Rayzon Energy Private Limited and INOX Solar Limited. These contracts are for Ultra-Pure Water systems, Effluent Treatment Plants (ETP), and Zero Liquid Discharge (ZLD) systems. Rayzon Energy's contract is worth approximately ₹95 crores for their 5.1 GW PV Solar project. INOX Solar's contract amounts to approximately ₹110 crores for ultrapure water generation, wastewater treatment, and zero liquid discharge.
Key Highlights
Secured contracts aggregating to approximately ₹205 Crores
Rayzon Energy contract is approximately ₹95 Crore
INOX Solar contract is approximately ₹110 Crore
Rayzon Energy project is for a 5.1 GW PV Solar project
Execution timeframe is 9 months and 10 months respectively
👀 What to Watch
This order book expansion is a positive sign. Investors should monitor the company's execution of these projects and their impact on future revenue and profitability.
